Roche’s Columvi offers survival benefit in Phase III DLBCL trial

Roche has released data from the Phase III STARGLO trial where its therapy Columvi (glofitamab) plus gemcitabine plus oxaliplatin (GemOx) improved overall survival (OS) in relapsed or refractory (R/R) DLBCL patients.